Sunday, November 8, 2009

Top Five Global Pharmaceutical Leader Selects Model N Revenue Management Suite

Top Five Global Pharmaceutical Leader Selects Model N Revenue Management Suite

Another Top Pharma Selection for Model N Establishes Model N's Commercial Pharma Applications as the Industry Standard

Redwood Shores, California (PRWEB) February 16, 2010

Model N (http://www. modeln. com), Inc., the leader in Revenue Management solutions, today announced that a global top five pharmaceuticals leader has selected Model N's full Pharmaceutical Commercial Revenue Management Suite to align its pricing, contracting, and settlements processes across its North American operations. The selection comes after an extensive evaluation by the customer of competitive offerings, including new products from its legacy software vendors.

"This selection is another example of the strong market momentum Model N is experiencing among top ten pharmaceutical companies," said Sujay Jadhav, General Manager, Life Sciences, at Model N. "The three top ten wins Model N has posted over the last year reflect the trust that large, global Life Science enterprises have placed in us to meet their unique business needs. We've helped strengthen that trust by delivering powerful international Revenue Management and advanced analytics capabilities in v.5.4 of our Revenue Management Suite and will continue to build our leadership in product and domain expertise to help our customers stay ahead of a rapidly evolving global life science market."

Expanding Globally
Global industry leaders are increasingly turning to Model N's proven, best-of-breed Revenue Management solutions to address growing pricing and contract complexity, changing regulatory requirements, and competitive and reimbursement pressures. To respond to these challenges, Model N has enhanced its Revenue Management Application Suite with significant new functionality, powerful analytics, and unique capabilities for the global market. This newest addition to the Model N customer community will be leveraging Model N's proven commercial pharmaceutical applications as a platform to drive new customer-tailored product and contracting strategies while simultaneously maintaining compliance with changing federal and state mandates. Model N's integrated, end-to-end application suite will replace an aging legacy system.

Deployment Details
 Model N will allow the company to enhance the entire commercial revenue life cycle, automating many functions that over the years have been added as manual workarounds  Enhanced contract management capabilities will allow the company to efficiently handle growing contracting volume and more quickly respond to market opportunity with new contracting strategies  The Model N system will meet an increased need for granular, real-time information to drive strategic decision making (analytics, deal analysis, forecasting, cross-organizational data sharing)  Seamless integration with customer's SAP ERP solution will accelerate time to value Supporting Resources

AMR Research: Model N Thinks Globally with 5.4 Release (https://tw2l. market2lead. com/go/modeln/amr_5_4)

AMR Research: Will Healthcare Reform Cause Model N's Next Growth Spurt? (https://tw2l. market2lead. com/go/modeln/AMR_10_09)

Model N Life Science Revenue Management Suite (http://www. modeln. com/lifeScience/solutions/)

About Model N
Model N is the leader in Revenue Management solutions, offering an integrated suite of applications for analytics, pricing strategy and execution, contracts, compliance, rebates, fees and chargebacks optimized for the industry practices of Life Sciences and High Tech companies. Enabling the creation of a seamless, end-to-end process from price setting through settlements payment, Model N's uniquely integrated approach eliminates revenue leakage and delivers the visibility and controls needed to avoid the risks of non-compliance to government reporting regulations such as Sarbanes-Oxley and government pricing requirements. Customers include: Boston Scientific Corporation; Bristol-Myers Squibb Company; Cypress Semiconductor Corporation; Intersil Corporation; Linear Technology Corporation; Medtronic, Inc.; Microchip Technology Inc.; Micron Technology Inc.; Ortho-Clinical Diagnostics, a Johnson & Johnson company; ON Semiconductor, Inc. Pfizer, Inc.; and STMicroelectronics. Model N is located in Redwood Shores, California. For additional information, visit www. modeln. com.

###